Recent Updates
Recently added Catalysts
BLTE Positive Sentiment Score: 70/100

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Monday, March 17, 2025 1 min read
Key Takeaway: Belite Bio, a clinical-stage biopharmaceutical company, announced the availability of its annual report on Form 20-F for the fiscal year ending December 31, 2024. The report, which includes audited consolidated financial statements, can be accessed on the company's website. Shareholders can request a hard copy of the report free of charge. Belite is advancing therapeutics for retinal diseases and has its lead candidate, Tinlarebant, actively undergoing Phase 3 and Phase 2/3 studies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Availability of the annual report increases transparency for investors.
  • Belite Bio is focused on addressing significant unmet medical needs in retinal diseases.
  • Lead candidate Tinlarebant is in advanced stages of clinical evaluation.

Full Press Release Details

Belite Bio Announces Availability of Annual
Through Company Website
SAN DIEGO, March 17, 2025- Belite Bio, Inc
(NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report
on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities
and Exchange Commission on March 17, 2025, is available through its website (https://www.belitebio.com). Shareholders may receive
a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).
Belite Bio is a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet
medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD),
in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation
of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1
visit us at www.belitebio.com
Media and Investor Relations Contact:
belite@argotpartners.com

Frequently Asked Questions

Where can I find Belite Bio's annual report?

Belite Bio's annual report is available on their website at www.belitebio.com.

What is the date of Belite Bio's annual report release?

The annual report was released on March 17, 2025.

How can shareholders obtain a hard copy of the annual report?

Shareholders can request a hard copy of the annual report free of charge.

What does Belite Bio focus on in its research?

Belite Bio develops therapies for degenerative retinal diseases and metabolic diseases.

What is Tinlarebant and its purpose?

Tinlarebant is an oral therapy aimed at reducing toxic accumulation in the eye.

Tags: BLTE Viatris Investor Conferences Healthcare Belite Bio retinal diseases Tinlarebant financial report
Last updated: Mar 17, 2025